show episodes
 
e
eHeme Malignancies Review
Rare
 
Dr. Mikkael Sekeres will cover important issues related to Myelodysplastic Syndromes in the format of case-study scenarios
 
P
PeerVoice Haematology Video
Rare
 
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
 
Loading …
show series
 
Listen as Dr. Harvey will discuss rash management for patients taking IRd.
 
Webcast: European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2017
 
Webcast: European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2017
 
In the news this week, the launch of NeuroCDRD – a new initiative to accelerate development of treatments for neuro diseases; OICR researchers invent a new molecular barcode technology; and Aurinia Phramceuticals prices a US$150.5 million public offering of common shares. We have all this and more coming up on Biotechnology Focus Radio. Story 1 ...…
 
Listen as Dr. Donald Harvey explains which prophylactic antithrombotic agents are safe to use with lenalidomide.
 
Listen as Dr. Donald Harvey explains how he manages renal dysfunction in a patient who is taking lenalidomide.
 
ResearchToPractice.com/MTPMDS116 - Meet The Professors: A Case-Based Discussion on the Management of Myelodysplastic Syndromes. Discussion with Harry P Erba, MD, PhD, Guillermo Garcia-Manero, MD, Warren Brenner, MD, Neil I Morganstein, MD and Erik J Rupard, MD moderated by Neil Love, MD. Produced by Research To Practice.…
 
Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may not affect the myeloma stem cells. Dr. Matsui recently presented results from a study he did with colleagues at Johns ...…
 
Health Update Welcome to the show everyone! I hope you are all well! Usually, I would be introducing my guest right now, but we had some technical difficulties with Skype and had to reschedule the interview. That interview should be coming up soon, probably in the next few weeks. I thought this would be a good time to give you all an update on ...…
 
L
Listen to The Lancet Haematology
 
Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.
 
The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.By Paul M. Barr.
 
Lenalidomide is a promising agent for the treatment of mantle cell lymphoma.By Brian G. Till.
 
H
Hematologic Oncology Update
 
ASHRLD11 - A 54-year-old woman with MM and normal cytogenetics receives lenalidomide, bortezomib and dexamethasone (RVD) on the SWOG-S0777 study followed by maintenance lenalidomide. Case discussion moderated by Neil Love, MD. Produced by Research To Practice.By Neil Love, MD.
 
(December 10, 2010 - Insidermedicine) From Michigan - A new drug combination shows success in treating multiple myeloma, according to a report presented at the American Society of Hematology meeting. Researchers administered a combination of carfilzomib, lenalidomide and low-dose dexamethasone in 31 multiple myeloma patients. Results showed an ...…
 
(December 10, 2010 - Insidermedicine) From Michigan - A new drug combination shows success in treating multiple myeloma, according to a report presented at the American Society of Hematology meeting. Researchers administered a combination of carfilzomib, lenalidomide and low-dose dexamethasone in 31 multiple myeloma patients. Results showed an ...…
 
Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.
 
ResearchToPractice.com/MTPH109 – Case 8 from the practice of Lowell L Hart, MD presented to Drs Gregory and Orlowski, moderated by Neil Love, MD. A 70-year-old woman with MM experienced a near-complete remission with reduced-dose lenalidomide/dexamethasone followed by pamidronate maintenance therapy. Produced by Research To Practice.…
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login